NIPPON KINZOKU: Announcement of Opening Trial Production & Consignment Processing Support Desk
NIPPON KINZOKU CO., LTD. (TOKYO:5491) (Head office: Minato-ku, Tokyo) will open a "Trial Products & Consignment Processing Support Desk" on Tuesday, April 1, 2025, with the aim of creating new partnerships with customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250225365935/en/
NIPPON KINZOKU's facilities, technologies, functions, and network can meet all your development and trial production needs. (Graphic: Business Wire)
We will newly establish a specialized department, "Production Process & Support Dept.” to handle trial productions, samples, and consignment processing, and will begin accepting inquiries.
“Trial Production & Consignment Processing Support Desk” will respond to all development and trial production needs by utilizing our facilities, technologies, and capabilities in rolling, forming, and welded drawn pipe to meet the ever-changing market needs for our customers' product development.
Features of the Service
- Specialized department will respond to a variety of consultation needs
Based on our R&D facilities and many years of accumulation with processing technology, we work together with customers to solve a variety of problems. - Support from the development stage to trial and mass production
We provide consistent and comprehensive support from the customer's idea conception and development study stage to trial and mass production. - Consignment and complex/specialized processing are also available
Our highly precise, functional facilities and extensive network of business partners enable us to offer a wide range of services, including material rolling, heat treatment, various surface treatments, profile rolling, roll forming, composite molding, precision pipe forming (welded and drawn pipes), precision pressing, and we also undertake various types of consignment processing.
*Click here for a list of materials and processing support - Prompt delivery of trial products and speedy response to small-quantity sample requests
We will provide samples of a few pieces or a few kilograms with the shortest delivery time and expand our sample inventory in addition to our small-lot inventory of stainless steel strips.
We will renew our website on April 1, 2025, and open a “Trial Production & Consignment Processing Support Desk” page. Regardless of the material we handle or the range of our manufacturing, we will play a role in your product development process through the Nippon Kinzoku’s network and support you in realizing your mass production, so please feel free to consult us at any time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225365935/en/
Contacts
Sales Development Dept.
NIPPON KINZOKU CO., LTD.
E-mail: nikkin-overseas@nipponkinzoku.co.jp
https://www.nipponkinzoku.co.jp/en/inquiry -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nipponkinz
oku.co.jp%2Fen%2Finquiry&esheet=54210588&newsitemid=20250225365935&lan=en-US&anc
hor=https%3A%2F%2Fwww.nipponkinzoku.co.jp%2Fen%2Finquiry&index=2&md5=30b44ce418c
1d66e9d04e4201c83ebe0
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release
Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom